why choose us

First received: November 15, 2022

Clinical Trial: Disulfiram for Treatment of Retinal Degeneration

Study Status: Completed

Recruit Status: RECRUITING

Condition: Inherited Retinal Dystrophy Primarily Involving Sensory Retina

Study Type: INTERVENTIONAL


Official Title: A Cross-over Randomized Control Trial to Evaluate the Retinaldehyde Dehydrogenase Inhibitor, Disulfiram, in Improving Retinal Sensitivity in Eyes Affected by Inherited Retinal Degeneration

Brief Summary: Aberrant retinoic acid signaling driven by the degenerating outer retina leads to pathological changes to the inner retina.The resulting hyperactivity of retinal ganglion cells leads to further diminution of the remaining vision in those afflicted with inherited retinal diseases.Inhibition of this pathway has led to improved visual function in murine models of retinal degeneration.This can be accomplished in humans with the FDA-approved irreversible inhibitor of aldehyde dehydrogenases, disulfiram.

Read more